MITF and melanoma: We show here that KO, KD, or pharmacological inhibition of Rab7a or TPC2 results not only in reduced proliferation, but also in reduced invasion and migration, most consistently in high MITF expressing melanoma lines, which after TPC2 or Rab7a KO or KD, or TPC2 inhibitor treatment (SG-094) show much reduced or absent MITF expression, in line with the reduction in β-Catenin levels found for the KOs in vitro and in vivo.